807.71
-7.08 (-0.87%)
| Penutupan Terdahulu | 814.79 |
| Jumlah Dagangan | 611,729 |
| Harga / Pendapatan (P/E Ke hadapan) | 17.36 |
| Harga / Jualan (P/S) | 5.61 |
| Harga / Buku (P/B) | 2.65 |
| Julat 52 Minggu | |
| Hasil Dividen (DY TTM) | 0.57% |
| Margin Keuntungan | 31.94% |
| Margin Operasi (TTM) | 19.94% |
| EPS Cair (TTM) | 39.36 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | -3.70% |
| Pertumbuhan Pendapatan Suku Tahunan (YOY) | 12.00% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 9.20% |
| Nisbah Semasa (MRQ) | 4.93 |
| Aliran Tunai Operasi (OCF TTM) | 3.95 B |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | 2.08 B |
| Pulangan Atas Aset (ROA TTM) | 6.91% |
| Pulangan Atas Ekuiti (ROE TTM) | 15.96% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Bercampur | Menaik |
| Biotechnology (Global) | Bercampur | Menaik | |
| Stok | Regeneron Pharmaceuticals, Inc. | Bercampur | Menaik |
AISkor Stockmoo
| Konsensus Penganalisis | NA |
| Aktiviti Orang Dalam | -2.5 |
| Volatiliti Harga | -1.5 |
| Purata Bergerak Teknikal | -1.0 |
| Osilator Teknikal | 4.0 |
| Purata | -0.20 |
|
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has early-stage partnerships that bring new technology to the pipeline, including RNAi (Alnylam) and Crispr-based gene editing (Intellia). |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Large Value |
| % Dimiliki oleh Orang Dalam | 1.89% |
| % Dimiliki oleh Institusi | 91.98% |
Tiada data dalam julat masa ini.
| Nama | Purata Belian ($) | Purata Jualan ($) | Jumlah Net | Jumlah Nilai Bersih ($) |
|---|---|---|---|---|
| FENIMORE CHRISTOPHER R. | - | 810.24 | -4,599 | -3,726,294 |
| LAROSA JOSEPH J | - | 840.84 | -9,019 | -7,583,536 |
| Jumlah Keseluruhan Kuantiti Bersih | -13,618 | |||
| Jumlah Keseluruhan Nilai Bersih ($) | -11,309,830 | |||
| Purata Pembelian Keseluruhan ($) | - | |||
| Purata Jualan Keseluruhan ($) | 825.54 | |||
| Nama | Pemegang | Tarikh | Jenis | Kuantiti | Harga | Nilai ($) |
|---|---|---|---|---|---|---|
| LAROSA JOSEPH J | Pegawai | 19 Aug 2026 | Dibuang (-) | 9,019 | 840.84 | 7,583,536 |
| LAROSA JOSEPH J | Pegawai | 19 Aug 2026 | Pelaksanaan pilihan | 12,282 | - | - |
| FENIMORE CHRISTOPHER R. | Pegawai | 18 Aug 2026 | Dibuang (-) | 4,599 | 810.24 | 3,726,294 |
| FENIMORE CHRISTOPHER R. | Pegawai | 18 Aug 2026 | Pelaksanaan pilihan | 6,283 | - | - |
| Tarikh | Jenis | Butiran |
|---|---|---|
| 29 Jun 2026 | CNBC | Eli Lilly, Regeneron among first companies selected for FDA initiative to speed review of new manufacturing facilities |
| Hasil Dividen (DY TTM) | 0.57% |
| Purata Hasil Dividen 1T | 0.46% |
| Nisbah Pembayaran | 2.24% |
| Tarikh EX | Tarikh Pengumuman | Tarikh Pembayaran | Perincian |
|---|---|---|---|
| 18 Aug 2026 | - | 31 Aug 2026 | 0.94 Tunai |
| 20 May 2026 | - | 04 Jun 2026 | 0.94 Tunai |
| 20 Feb 2026 | - | 05 Mar 2026 | 0.94 Tunai |
| 20 Nov 2025 | - | 05 Dec 2025 | 0.88 Tunai |
| 18 Aug 2025 | - | 03 Sep 2025 | 0.88 Tunai |
| 20 May 2025 | - | 06 Jun 2025 | 0.88 Tunai |
| 20 Feb 2025 | - | 20 Mar 2025 | 0.88 Tunai |
Hasil Dividen Tahunan
| Tahun | Dividen Tahunan ($) | Kekerapan/Tahun | Hasil % |
|---|---|---|---|
| 2026 | 2.82 | 3 | 0.35 |
| 2025 | 3.52 | 4 | 0.46 |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |